News | April 19, 2025
Aptar commences clinical study to accelerate FDA approval of SmartTrack
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
A centralised kitchen which provides 5,000 breakfast meals per day is to be started at Perumallapuram, Kakinada, Andhra Pradesh
It recognizes the company's commitment to safeguarding sensitive data, protecting patient information
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Subscribe To Our Newsletter & Stay Updated
